Specific inhibition of hepatitis C virus replication by cyclosporin A

Biochemical and Biophysical Research Communications

Volumn 313, Issue 1, 2004, Pages 42-47

  Nakagawa, Mina ^a   Sakamoto, Naoya ^a   Enomoto, Nobuyuki ^a   Tanabe, Yoko ^a   Kanazawa, Nobuhiko ^a   Koyama, Tomoyuki ^a   Kurosaki, Masayuki ^a   Maekawa, Shinya ^a   Yamashiro, Tsuyoshi ^a   Chen, Cheng Hsin ^a   Itsui, Yasuhiro ^a   Kakinuma, Sei ^a   Watanabe, Mamoru ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Cyclophilins; Cyclosporin A; FK506; Hepatitis C virus; ISRE; Replicon

Indexed keywords

CYCLOSPORIN A; INTERFERON; KANAMYCIN KINASE; LUCIFERASE; TACROLIMUS;

ANTIVIRAL ACTIVITY; ARTICLE; CELL GROWTH; CELL LINE; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; GENE EXPRESSION; GENETIC CODE; GENETIC TRANSFECTION; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; REPLICON; REPORTER GENE; VIRUS INHIBITION; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 10744223246     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.11.080     Document Type: Article

References (36)

1. Alter M.J. Epidemiology of hepatitis C. Hepatology. 26:1997;62S-65S.
2. Tong M.J., El-Farra N.S., Reikes A.R., Co R.L. Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med. 332:1995;1463-1466.
3. Davis G.L., Esteban-Mur R., Rustgi V., Hoefs J., Gordon S.C., Trepo C., Shiffman M.L., Zeuzem S., Craxi A., Ling M.H., Albrecht J. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339:1998;1493-1499.
4. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., Albrecht J.K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339:1998;1485-1492.
5. K. Sekiyama, M. Yoshiba, K. Inoue, in: Fourth International Symposium on Hepatitis C and Related Virus, Kyoto, Japan, 1997.
6. Inoue K., Sekiyama K., Yamada M., Watanabe T., Yasuda H., Yoshiba M. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J. Gastroenterol. 38:2003;567-572.
7. Matsuda S., Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 47:2000;119-125.
8. Lohmann V., Koerner F., Koch J., Herian U., Theilmann L., Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 285:1999;110-113.
9. Guo J.T., Bichko V.V., Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J. Virol. 75:2001;8516-8523.
10. Yokota T., Sakamoto N., Enomoto N., Tanabe Y., Miyagishi M., Maekawa S., Yi L., Kurosaki M., Taira K., Watanabe M., Mizusawa H. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep. 4:2003;602-608.
11. Matsuda S., Moriguchi T., Koyasu S., Nishida E. T lymphocyte activation signals for interleukin-2 production involve activation of MKK6-p38 and MKK7-SAPK/JNK signaling pathways sensitive to cyclosporin A. J. Biol. Chem. 273:1998;12378-12382.
12. Frese M., Pietschmann T., Moradpour D., Haller O., Bartenschlager R. Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J. Gen. Virol. 82:2001;723-733.
13. Handschumacher R.E., Harding M.W., Rice J., Drugge R.J., Speicher D.W. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science. 226:1984;544-547.
14. Hait W.N., Harding M.W., Handschumacher R.E. Calmodulin, cyclophilin, and cyclosporin A. Science. 233:1986;987-989.
15. Jiang H., Suguo H., Takahara S., Takano Y., Li D., Kameoka H., Moutabarrik A., Kokado Y., Ishibashi M., Okuyama A.et al. Combined immunosuppressive effect of FK 506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro. Transplant. Proc. 23:1991;2933-2936.
16. Sigal N.H., Dumont F., Durette P., Siekierka J.J., Peterson L., Rich D.H., Dunlap B.E., Staruch M.J., Melino M.R., Koprak S.L.et al. Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A? J. Exp. Med. 173:1991;619-628.
17. Nilsson B., Anderson S. Proper and improper folding of proteins in the cellular environment. Annu. Rev. Microbiol. 45:1991;607-635.
18. Brandts J.F., Halvorson H.R., Brennan M. Consideration of the possibility that the slow step in protein denaturation reactions is due to cis-trans isomerism of proline residues. Biochemistry. 14:1975;4953-4963.
19. Braaten D., Luban J. Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. EMBO J. 20:2001;1300-1309.
20. Bartenschlager R., Lohmann V. Replication of hepatitis C virus. J. Gen. Virol. 81:2000;1631-1648.
21. Mottola G., Cardinali G., Ceccacci A., Trozzi C., Bartholomew L., Torrisi M.R., Pedrazzini E., Bonatti S., Migliaccio G. Hepatitis C virus nonstructural proteins are localized in a modified endoplasmic reticulum of cells expressing viral subgenomic replicons. Virology. 293:2002;31-43.
22. Choukhi A., Ung S., Wychowski C., Dubuisson J. Involvement of endoplasmic reticulum chaperones in the folding of hepatitis C virus glycoproteins. J. Virol. 72:1998;3851-3858.
23. Waxman L., Whitney M., Pollok B.A., Kuo L.C., Darke P.L. Host cell factor requirement for hepatitis C virus enzyme maturation. Proc. Natl. Acad. Sci. USA. 98:2001;13931-13935.
24. Harrison R.K., Stein R.L. Substrate specificities of the peptidyl prolyl cis-trans isomerase activities of cyclophilin and FK-506 binding protein: evidence for the existence of a family of distinct enzymes. Biochemistry. 29:1990;3813-3816.
25. Paslaru L., Pinto M., Morange M. GRP78 induction by cyclosporin A in human HeLa cells. FEBS Lett. 350:1994;304-308.
26. Gamble T.R., Vajdos F.F., Yoo S., Worthylake D.K., Houseweart M., Sundquist W.I., Hill C.P. Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell. 87:1996;1285-1294.
27. Bosco D.A., Eisenmesser E.Z., Pochapsky S., Sundquist W.I., Kern D. Catalysis of cis/trans isomerization in native HIV-1 capsid by human cyclophilin A. Proc. Natl. Acad. Sci. USA. 99:2002;5247-5252.
28. Steinkasserer A., Harrison R., Billich A., Hammerschmid F., Werner G., Wolff B., Peichl P., Palfi G., Schnitzel W., Mlynar E.et al. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication. J. Virol. 69:1995;814-824.
29. Berenguer M., Crippin J., Gish R., Bass N., Bostrom A., Netto G., Alonzo J., Garcia-Kennedy R., Rayon J.M., Wright T.L. A model to predict severe HCV-related disease following liver transplantation. Hepatology. 38:2003;34-41.
30. Seeff L.B., Buskell-Bales Z., Wright E.C. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N. Engl. J. Med. 327:1992;1906-1911.
31. Berenguer M., Prieto M., San Juan F., Rayon J.M., Martinez F., Carrasco D., Moya A., Orbis F., Mir J., Berenguer J. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology. 36:2002;202-210.
32. T.U.S.M.F.L.S. Group, A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The US Multicenter FK506 Liver Study group, N. Engl. J. Med. 331 (1994) 1110-1115.
33. Moore R., Lord R. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet. 344:1994;423-428.
34. O'Grady J.G., Burroughs A., Hardy P., Elbourne D., Truesdale A. Tacrolimus versus microemulsified cyclosporin in liver transplantation: the TMC randomised controlled trial. Lancet. 360:2002;1119-1125.
35. Bierer B.E., Somers P.K., Wandless T.J., Burakoff S.J., Schreiber S.L. Probing immunosuppressant action with a nonnatural immunophilin ligand. Science. 250:1990;556-559.
36. Berenguer M., Wright T.L. Hepatitis C and liver transplantation. Gut. 45:1999;159-163.